REG - AstraZeneca PLC - Previous Announcement Regarding Appointment Of NED

AstraZenecaAnnouncement

28/09/2018 16:00

RNS Number : 3957C
AstraZeneca PLC
28 September 2018
 


28 September 2018 16:00 BST
 
PREVIOUS ANNOUNCEMENT REGARDING APPOINTMENT OF NON-EXECUTIVE DIRECTOR
 
AstraZeneca PLC (the Company) today announced that with the Company's agreement, Joseph G. Peter (Joe Peter) has withdrawn his candidacy as a Non-Executive Director and a member of the Audit Committee.  His proposed appointment to these positions was announced by the Company on 6 September 2018 and was to have become effective on 1 October 2018.  Mr Peter's decision is for reasons that are not related to the Company.
 
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.



Media Relations












Karen Birmingham


UK/Global


+44 203 749 5634




Rob Skelding


UK/Global


+44 203 749 5821




Matt Kent


UK/Global


+44 203 749 5906




Gonzalo Viña


UK/Global


+44 203 749 5916




Jacob Lund


Sweden


+46 8 553 260 20




Michele Meixell


US


+1 302 885 2677


















  Investor Relations










 




Thomas Kudsk Larsen






+44 203 749 5712




Henry Wheeler


Oncology


+44 203 749 5797




Christer Gruvris


Cardiovascular; Metabolism


+44 203 749 5711




Nick Stone


Respiratory; Renal


+44 203 749 5716




Josie Afolabi


Other


+44 203 749 5631




Craig Marks


Finance; Fixed Income


+44 7881 615 764




Jennifer Kretzmann


Retail Investors


+44 203 749 5824




US toll-free






+1 866 381 7277










 
Adrian Kemp

Company Secretary
AstraZeneca PLC




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
BOAZVLFLVKFLBBZ